


#4



Date: March 20, 2002 Label No. EV074199717US

I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

Dawn M. Berry

Name (Print)

Dawn M. Berry

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Kyogo ITOH

Application No.: 10/062,257

Filed: February 1, 2002

)  
)  
)  
)  
)  
)

Group Art Unit: 1646

Examiner: To Be Assigned

For: TUMOR ANTIGEN

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 CFR 1.97(b)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

March 20, 2002

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. One copy of each of these documents is attached.

This Information Disclosure Statement is being submitted before expiration of the three-month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or

constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925 and please consider this a petition.

Respectfully submitted,



Luke A. Kilyk  
Reg. No. 33,251

Atty. Docket No.: 3190-014  
KILYK & BOWERSOX, P.L.L.C.  
53A Lee Street  
Warrenton, VA 20186  
Tel: (540) 428-1701  
Fax: (540) 428-1720  
Enclosures: PTO-1449, w/5 Documents



FORM PTO-1449 (REV 7-80)				Applicant Docket No. 3190-014		Application No. 10/062,257	
<b>INFORMATION DISCLOSURE STATEMENT</b>				APPLICANT: Kyogo ITOH			
				Filing Date: February 1, 2002		Group Art Unit: 1646	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE, IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	Megumi KIKUCHI, et al., "Identification of a Sart-1-Derived Peptide Capable of Inducing HLA-A24-Restricted and Tumor-Specific Cytotoxic T Lymphocytes", <u>Int. J. Cancer</u> , 1999, Vol. 81, pgs. 459-466.						
	Yasuhiro KOGA, et al., "A Human T Cell-Specific cDNA Clone (YT16) Encodes A Protein With Extensive Homology To A Family of Protein-Tyrosine Kinases", <u>Eur. J. Immunol.</u> 1986, Vol. 16, pgs. 1643-1646.						
	Akio TANAKA, et al., "DNA Sequence Encoding The Amino-Terminal Region of the Human c-src Protein: Implications of Sequence Divergence Among src-Type Kinase Oncogenes", <u>Molecular and Cellular Biology</u> , May 1987, pgs. 1978-1983.						
	Nanae HARASHIMA, et al., "Recognition of the Lck Tyrosine Kinase as a Tumor Antigen by Cytotoxic T Lymphocytes of Cancer Patients with Distant Metastases", <u>Eur. J. Immunol.</u> , 2001, Vol. 31, pgs. 323-332.						
	Nobue IMAI, et al., "Identification of Lck-Derived Peptides Capable of Inducing HLA-A2-Restricted and Tumor-Specific CTLs in Cancer Patients with Distant Metastases", <u>Int. J. Cancer</u> , 2001; Vol. 94, pgs. 237-242.						
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							